Correlation between different p53 expression patterns and chromosome 17 imbalances in pancreatic ductal adenocarcinoma based on tissue microarray analysis

Journal of B.U.ON.

Volumn 15, Issue 1, 2010, Pages 94-100

  Tsiambas, Evangelos ^a   Kravvaritis, C ^b   Tsounis, D ^c   Salemis, N S ^d   Niotis, A ^e   Niotis, T H ^e   Rigopoulos, D N ^d   Karameris, A ^e   Athanasiou, A E ^f   Patsouris, E ^a   Karakitsos, P ^g  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b Forensic Service   (Greece)

^c 251 Air Force Hospital   (Greece)

^d 401 GENERAL MILITARY HOSPITAL OF ATHENS   (Greece)

^e NIMTS HOSPITAL   (Greece)

^f METAXA CANCER HOSPITAL   (Greece)

^g UNIVERSITY OF ATHENS   (Greece)

Author keywords

Chromogenic in situ hybridization; Chromosome; p53; Pancreatic ductal adenocarcinoma; Tissue microarrays

Indexed keywords

PROTEIN P53;

ADULT; AGED; ALLELE; ANEUPLOIDY; ARTICLE; CANCER GRADING; CANCER STAGING; CENTROMERE; CHROMOGENIC IN SITU HYBRIDIZATION; CHROMOSOME 17; CHROMOSOME 17P; CHROMOSOME ABERRATION; DIGITAL IMAGING; FEMALE; GENE EXPRESSION REGULATION; GENE LOCATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; MALE; MONOSOMY; MUTANT; P53 GENE; PANCREAS ADENOCARCINOMA; POINT MUTATION; TISSUE MICROARRAY; TUMOR SUPPRESSOR GENE; WILD TYPE;

AGED; ANEUPLOIDY; CARCINOMA, PANCREATIC DUCTAL; CHI-SQUARE DISTRIBUTION; CHROMOSOMES, HUMAN, PAIR 17; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; MIDDLE AGED; NEOPLASM STAGING; PANCREATIC NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 77951000896     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Moore PS, Beghelli S, Zamboni G, Scarpa A. Genetic abnormalities in pancreatic cancer. Mol Cancer 2003; 2: 7-16
2. Talar-Wojnarowska R, Malecka-Panas E. Molecular pathogenesis of pancreatic adenocarcinoma: potential clinical implications. Med Sci Monit 2006; 12: 186-193.
3. Adsay NV, Basturk O, Cheng JD, Andea AA. Ductal neoplasia of the pancreas: nosologic, clinicopathologic, and biologic aspects. Semin Radiat Oncol 2005; 15: 254-264.
4. Leppard K, Totty N, Waterfield M, Harlow E, Jenkins J, Crawford L. Purification and partial amino acid sequence analysis of the cellular tumour antigen, p53, from mouse S V40-transformed cells. EMBO J 1983; 2: 1993-1999.
5. Malecka KA, Ho WC, Marmorstein R. Crystal structure of a p53 core tetramer bound to DNA. Oncogene 2009; 28: 325-333.
6. Vojtěšek B, Bártek J, Midgley CA, Lane DP. An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53. J Immunol Methods 1992; 151: 237-244.
7. Bártek J, Bártková J, Vojtěšek B et al. Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene 1991; 6: 1699-1703.
8. Brody JR, Costantino CL, Potoczek M et al. Adenosquamous carcinoma of the pancreas harbors KRAS2, DPC4 and TP53 molecular alterations similar to pancreatic ductal adenocarcinoma. Mod Pathol 2009; 22: 651-659.
9. Awadallah NS, Shroyer KR, Langer DA et al. Detection of B7-H4 and p53 in pancreatic cancer: potential role as a cytological diagnostic adjunct. Pancreas 2008; 36: 200-206.
10. Ohtsubo K, Watanabe H, Yao F et al. Preproencephalin hypermethylation in the pure pancreatic juice compared with p53 mutation in the diagnosis of pancreatic carcinoma. J Gastroenterol 2006; 41: 791-797.
11. Brune K, Hong SM, Li A, Yachida S. Genetic and epigenetic alterations of familial pancreatic cancers. Cancer Epidemiol Biomarkers Prev 2008; 17: 3536-3542.
12. Kloppel G, Hruban RH, Longnecker DS, Adler G, Kern SE, Partanen TJ. Ductal adenocarcinoma of the pancreas. In: Hamilton SR, Aaltonen LA (Eds): Pathology and Genetics of Tumours of the Digestive System. Lyon, France: IARC Press, 2000, pp 221-230.
13. Siveke JT, Schmid RM. Chromosomal instability in mouse metastatic pancreatic cancer - it's Kras and Tp53 after all. Cancer Cell 2005; 7: 405-407.
14. Hermanová M, Lukás Z, Kroupová I. Relationship between K-ras mutation and the expression of p21 WAF1/CIP1 and p53 in chronic pancreatitis and pancreatic adenocarcinoma. Neoplasma 2003; 50: 319-325.
15. Yamasawa K, Nio Y, Dong M, Yamaguchi K, Itakura M. Clinicopathological significance of abnormalities in Gadd45 expression and its relationship to p53 in human pancreatic cancer. Clin Cancer Res 2002; 8: 2563-2569. (Pubitemid 34856340)
16. Fryzek JP, Garabrant DH, Schenk M, Kinnard M, Greenson JK, Sarkar FH. The association between selected risk factors for pancreatic cancer and the expression of p53 and K-ras codon 12 mutations. Int J Gastrointest Cancer 2006; 37: 139-145. (Pubitemid 351642217)
17. Yan L, McFaul C, Howes N. Molecular analysis to detect pancreatic ductal adenocarcinoma in high-risk groups. Gastroenterology 2005; 128: 2124-2130. (Pubitemid 40824719)
18. Hermanova M, Trna J, Nenutil R, Dite P, Kala Z. Expression of COX-2 is associated with accumulation of p53 in pancreatic cancer: analysis of COX-2 and p53 expression in premalignant and malignant ductal pancreatic lesions. Eur J Gastroenterol Hepatol 2008; 20: 732-739.
19. Hashimoto K, Nio Y, Koike M. Expression of retinoblastoma and p53 pathway-related proteins in resectable invasive ductal carcinoma of the pancreas: potential cooperative effects on clinical outcome. Anticancer Res 2005; 25(2B): 1361-1368. (Pubitemid 40546816)
20. Biankin AV, Kench JG, Morey AL. Overexpression of p21 (WAF1/CIP1) is an early event in the development of pancreatic intraepitheUal neoplasia. Cancer Res 2001 ; 61: 8830-8837.
21. Ohshio G, Suwa H, Imamura M. Clinical implication of anti-p53 antibodies and p53-protein in pancreatic disease. Int J Gastrointest Cancer 2002; 31: 129-135. (Pubitemid 36330115)
22. Uemura K, Hiyama E, Murakami Y. Comparative analysis of K-ras point mutation, telomerase activity, and p53 overexpression in pancreatic tumours. Oncol Rep 2003; 10: 277-283.
23. Morton JP, Klimstra DS, Mongeau ME, Lewis BC. Trp53 deletion stimulates the formation of metastatic pancreatic tumors. Am J Pathol 2008; 172: 1081-1087.
24. Dong M, Nio Y, Yamasawa K, Toga T, Yue L, Harada T. p53 alteration is not an independent prognostic indicator, but affects the efficacy of adjuvant chemotherapy in human pancreatic cancer. J Surg Oncol 2003; 82: 111-120. (Pubitemid 36164446)
25. Franko J, Krasinskas AM, Nikiforova MN. Loss of heterozygosity predicts poor survival after resection of pancreatic adenocarcinoma. J Gastrointest Surg 2008; 12: 1664-1672.
26. Luttges J, Galehdari H, Brocker V et al. Allelic loss is often the first hit in the biallelic inactivation of the p53 and DPC4 genes during pancreatic carcinogenesis. Am J Pathol 2001; 158: 1677-1683. (Pubitemid 32422932)
27. Adsay NV, Dergham ST, Koppitch FC. Utility of fluorescence in situ hybridization in pancreatic ductal adenocarcinoma. Pancreas 1999; 18: 111-116.
28. Tsiambas E, Karameris A, Stamatelopoulos A et al. Chromogenic in situ hybridization analysis of chromosomes 7, 9, and 17 in pancreatic ductal adenocarcinoma based on tissue microarrays. J BUON 2006; 11: 205-211.
29. Furukawa T, Sunamura M, Horii A. Molecular mechanisms of pancreatic carcinogenesis. Cancer Sci 2006; 97: 1-7.
30. Stoecklein NH, Luebke AM, Erbersdobler A et al. Copy number of chromosome 17 but not HER2 amplification predicts clinical outcome of patients with pancreatic ductal adenocarcinoma. J Clin Oncol 2004; 22: 4737-4745. (Pubitemid 41185084)
31. Tsiambas E, Karameris A, Dervenis C et al. HER2/neu expression and gene alterations in pancreatic ductal adenocarcinoma: a comparative immunohistochemistry and chromogenic in situ hybridization study based on tissue microarrays and computerized image analysis. JOP 2006; 7: 283-294.
32. Tsiambas E, Karameris A, Tiniakos DG, Karakitsos P. Evaluation of topoisomerase IIa expression in pancreatic ductal adenocarcinoma: a pilot study using chromogenic in situ hybridization and immunohistochemistry on tissue microarrays. Pancreatology 2007; 7: 45-52. (Pubitemid 46725721)
33. Reinholz MM, Bruzek AK, Visscher DW. Breast cancer and aneusomy 17: implications for carcinogenesis and therapeutic response. Lancet Oncol 2009; 10: 267-277.
34. Gironella M, Seux M, Xie MJ. Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development. Proc Natl Acad Sci U S A 2007; 104: 16170-16175. (Pubitemid 350099380)
35. Kalid O, Ben-Tal N. Study of MDM2 binding to p53-analogues: affinity, helicity, and applicability to drug design. J Chem Inf Model 2009; 49: 865-876.